When should we use TNF antagonists in children with rheumatic disease?
- 31 January 2007
- journal article
- editorial
- Published by Elsevier BV in Joint Bone Spine
- Vol. 74 (1), 1-3
- https://doi.org/10.1016/j.jbspin.2006.07.001
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Etanercept for Psoriasis in the Pediatric Population: Experience in Nine PatientsPediatric Dermatology, 2006
- The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFα therapyJoint Bone Spine, 2005
- Anti–tumor necrosis factor α blockade in the treatment of juvenile spondylarthropathyArthritis & Rheumatism, 2005
- Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockadeThe Journal of Experimental Medicine, 2005
- Therapeutic efficacy of humanized recombinant anti–interleukin‐6 receptor antibody in children with systemic‐onset juvenile idiopathic arthritisArthritis & Rheumatism, 2005
- The German etanercept registry for treatment of juvenile idiopathic arthritisAnnals Of The Rheumatic Diseases, 2004
- Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset typeArthritis & Rheumatism, 2003
- Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trialArthritis & Rheumatism, 2003
- Onset of multiple sclerosis associated with anti-TNF therapyNeurology, 2001
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000